Physician profile
Yshay Shlesinger
NPI 1881799922
$502,387.71
in general payments reported to CMS, 2019-2025
63 companies · $42K in 2025
The $42K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $129K · 2020: $54K · 2021: $101K · 2022: $97K · 2023: $43K · 2024: $35K · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $94K · Food and Beverage: $14K · Consulting Fee: $7,820 · Travel and Lodging: $4,857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $94,161.94 |
| Food and Beverage | $13,764.73 |
| Consulting Fee | $7,820.00 |
| Travel and Lodging | $4,857.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $243,815.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76,499.14 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $48,800.36 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $45,537.18 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $24,594.99 | 2019-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $14,127.23 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $12,292.59 | 2019-2020 | |
| Corcept Therapeutics | $12,082.79 | 2019-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $10,528.77 | 2021-2025 | |
| Boehringer Ingelheim International Gmbh | $1,220.49 | 2023 | |
| Beta Bionics, INC. | $1,051.14 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Mannkind Corporation | $1,046.06 | 2019-2025 | Afrezza |
| Abbott Laboratories | $1,021.69 | 2019-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $852.04 | 2021-2025 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $659.88 | 2023-2025 | Contrave, Nexlizet, Nexletol |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $659.15 | 2019-2025 | Synthroid, Ubrelvy |
| Amgen INC. | $600.52 | 2019-2025 | Tepezza, Prolia, Evenity |
| Biohaven Pharmaceuticals, INC. | $538.91 | 2021 | |
| Ibsa Pharma INC. | $504.42 | 2019-2024 | Tirosint, Tirosint, Licart |
| Amarin Pharma, INC. | $499.55 | 2020-2021 | |
| Insulet Corporation | $499.28 | 2019-2025 | Omnipod |
| Medtronic, INC. | $442.25 | 2021-2025 | Minimed 780g |
| Radius Health, INC. | $433.76 | 2019-2025 | Tymlos |
| Esperion Therapeutics, INC. | $377.65 | 2020-2021 | |
| Tandem Diabetes Care, INC. | $335.91 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $259.40 | 2019-2025 | Strensiq |
| Xeris Pharmaceuticals, INC. | $244.65 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Horizon Therapeutics Plc | $236.93 | 2019-2023 | Tepezza |
| Becton, Dickinson and Company | $203.31 | 2021-2022 | |
| Halozyme INC | $195.17 | 2023 | |
| Zealand Pharma US, INC. | $187.13 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $180.05 | 2022 | |
| Exact Sciences Corporation | $178.63 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Tanabe Pharma America, INC. | $165.19 | 2023-2024 | |
| Antares Pharma, INC. | $154.83 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Novartis Pharmaceuticals Corporation | $152.79 | 2023-2025 | |
| Ascendis Pharma Endocrinology INC | $129.50 | 2023-2025 | Yorvipath |
| Ultragenyx Pharmaceutical INC. | $110.49 | 2020-2023 | |
| Nalpropion Pharmaceuticals LLC | $107.43 | 2019 | |
| Arbor Pharmaceuticals, INC. | $86.21 | 2019-2020 | |
| Companion Medical, INC. | $73.99 | 2019 | |
| Glaxosmithkline, LLC. | $71.84 | 2025 | Shingrix |
| Shire North American Group INC | $64.61 | 2019 | |
| Embecta Corp. | $61.51 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Cequr Corporation | $59.94 | 2022-2025 | Cequr Simplicity |
| Recordati_rare_diseases_inc. | $59.19 | 2023 | Signifor Lar, Isturisa |
| Pfizer INC. | $45.78 | 2023-2025 | |
| Almatica Pharma LLC | $44.11 | 2024 | Teriparatide |
| Bigfoot Biomedical INC | $42.88 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $35.34 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.64 | 2021-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $30.53 | 2024 | |
| Sun Pharmaceutical Industries INC. | $24.02 | 2020 | |
| Grt US Holding, INC. | $22.57 | 2021-2022 | |
| Alvogen INC | $21.32 | 2025 | Teriparatide |
| Ascensia Diabetes Care US INC. | $20.88 | 2024 | |
| Lifescan, INC. | $17.97 | 2020 | |
| Kyowa Kirin, INC. | $16.20 | 2024 | Crysvita |
| Endo Pharmaceuticals INC. | $15.62 | 2020 | |
| Sequel Med Tech, LLC | $15.15 | 2025 | Twiist |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$28,402.77 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yshay Shlesinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.